The U.S. Department of Health and Human Services and Department of Defense announced Tuesday an agreement with Moderna, Inc. to manufacture and deliver 100 million doses of the company’s COVID-19 vaccine candidate.

Moderna will manufacture the vaccine doses while clinical trials are underway. Manufacturing while conducting clinical trials expedites the traditional vaccine development timeline and builds toward the U.S. government’s Operation Warp Speed goal to begin delivering safe and effective vaccines to individuals by the end of the year, subject to successful clinical trials and FDA authorization.

If these doses are used in a COVID-19 vaccination campaign, the vaccine would be available to individuals at no cost and healthcare professionals could charge for the cost of administering the vaccine.